Doxycycline 100mg Capsules (Sinusitis — Penicillin Allergy)

The therapeutic indications section of this SPC lists, under Respiratory tract infections, 'Treatment of chronic bronchitis, sinusitis.' Sinusitis is therefore an expressly licensed indication for this product, by the oral route, in the population this page addresses. || WHICH REGIMEN APPLIES. §4.2 gives indication-specific regimens for acne vulgaris, sexually transmitted diseases, acute epididymo-orchitis, primary and secondary syphilis, louse- and tick-borne relapsing fevers, chloroquine-resistant falciparum malaria, malaria prophylaxis, scrub typhus prevention, travellers' diarrhoea prevention, leptospirosis prevention and Rocky Mountain spotted fever. Sinusitis is not among those named regimens, so the dose published above is the SPC's own general regimen 'for the treatment of acute infections', which is the regimen that covers a licensed acute respiratory-tract infection such as sinusitis. No indication-specific figure has been borrowed. In particular the acne dose (50 mg daily with food or fluid for 6 to 12 weeks) belongs to a different indication and to the other brand named on this page (Efracea); it has deliberately not been used. || VERBATIM (§4.2): 'The usual dosage of Vibramycin for the treatment of acute infections in adults and children aged 12 years to less than 18 years is 200 mg on the first day (as a single dose or in divided doses) followed by a maintenance dose of 100 mg/day. In the management of more severe infections, 200 mg daily should be given throughout treatment.' || PENICILLIN ALLERGY. The SPC does not itself frame doxycycline as a penicillin alternative for sinusitis. The only penicillin-alternative wording in §4.2 concerns syphilis ('Non-pregnant penicillin-allergic patients who have primary or secondary syphilis can be treated with the following regimen: doxycycline 200 mg orally twice daily for two weeks, as an alternative to penicillin therapy') — a different indication at a different dose. The choice of doxycycline in penicillin-allergic sinusitis is a guideline decision, not an SPC statement. || CHILDREN — NO CALCULATOR IS ARMED ON THIS PAGE, DELIBERATELY. paedDose is null. §4.2 does give per-kilogram figures for children aged 8 years to less than 12 years, verbatim: 'For children 45 kg or less - Initial dose: 4.4 mg/kg (in single or 2 divided doses) with maintenance dose: 2.2 mg/kg (in single or 2 divided doses). In the management of more severe infections, up to 4.4 mg/kg should be given throughout treatment.' and 'For children over 45 kg - Dose administered for adults should be used.' RATE READING: the SPC writes these as 'mg/kg' without a stated interval, but each is qualified 'in single or 2 divided doses', which makes the figure a DAILY TOTAL that may be split, not a per-dose amount — the same structure as the adult regimen it parallels (200 mg on day one, then 100 mg/day). Anyone re-encoding these must therefore treat 4.4 and 2.2 as mg/kg/day; taking either as a per-dose value would double the intended daily amount. Those figures are recorded here as prose only. They are NOT exposed as paedDose.dosePerKg because the SPC gates them behind conditions no numeric field can carry: the band is restricted to ages 8 to less than 12 years, to weights of 45 kg or less, and to 'situations where other drugs are not available, are not likely to be effective or are contraindicated' — a bar that penicillin-allergic sinusitis, which has alternatives, does not meet. §4.2 also states that 'Doxycycline should not be used in children aged younger than 8 years due to the risk of teeth discolouration', and a weight-only calculator cannot enforce an age floor. Children aged 12 to less than 18 years are covered by the adult dose published above. || ELDERLY (§4.2): 'Vibramycin may be prescribed in the elderly in the usual dosages with no special precautions... The Vibramycin-D dispersible tablet may be preferred for the elderly since it is less likely to be associated with oesophageal irritation and ulceration.' || TRUNCATION: §4.4 was cut mid-sentence in the beta-haemolytic streptococci paragraph and §4.8 inside the adverse-reaction reporting text. §4.1 and §4.2 are complete.